News wrap-up: This week’s headlines, plus USDA issues a conditional license for Elanco’s Canine Parvovirus Monoclonal Antibody

Happy Saturday dvm360® readers! We are less than 2 weeks away from our Directions in Veterinary Medicine symposium in Miami, Florida. Join us on May 19-20 for Targeted Education to Elevate Your Knowledge in Pain Management, where attendees will take a deep dive into pain management and earn up to 14.5 continuing education RACE-approved credits. Register here today to secure your spot!

While you start planning your trip to Miami, here is what was popular this week on dvm360.com:

• Elanco Animal Health Incorporated announced this week that it’s Canine Parvovirus Monoclonal Antibody has received conditional approval from the USDA, making it the first and only approved therapeutic solution to treat canine parvovirus and Elanco’s first monoclonal antibody.
• During an interview with dvm360®, Bryce Dooley, DVM, MS, DACAA, faculty for the Directions in Veterinary Medicine (DIVM) symposium in Miami, Florida, discussed what professionals should keep in mind when giving non-steroidal anti-inflammatory drugs.
• Galaxy Vets released “From Surviving to Thriving: Eliminate These Six Burnout Triggers from Your Veterinary Hospital,” a paper based on professional literature as well as internal research to help decrease burnout in the veterinary industry.
• On this week’s episode of The Vet Blast Podcast, Alexis Hansen, Bs, LVT, RVT, VTS (ECC), gives listeners and host Adam Christman, DVM, MBA, a refresher on transfusion medicine.
• The FDA has conditionally approved Varenzin-CA1 (molidustat oral suspension), the first drug for the control of nonregenerative anemia associated with chronic kidney disease for feline patients.
• And more!